Search results for: Search

Need a new search?

If you didn't find what you were looking for, try a new search!

Th17 Driven Diseases and CCR6

2017-04-27T18:12:41+00:00

Th17 Driven Diseases and CCR6 One of the most intriguing areas of current research in immunology involves a newly discovered type of helper T cells known as Th17 cells. There is a large amount of preclinical and clinical data that implicate Th17 cells, as well as IL-17, in the development of a large number [...]

Th17 Driven Diseases and CCR62017-04-27T18:12:41+00:00

Preclinical Candidates

2017-04-27T18:12:41+00:00

Preclinical Candidates for Immuno-Oncology One of the most exciting advances in oncology in decades is the recent observation that modifiers of the activity of the patient’s own immune system can profoundly enhance their response to chemotherapy. A critical cellular component of this response are the myeloid-derived suppressor cells (MDSCs), which inhibit the activity of [...]

Preclinical Candidates2017-04-27T18:12:41+00:00

Other Inflammatory and Autoimmune Diseases

2017-04-27T18:12:41+00:00

Other Inflammatory and Autoimmune Diseases Our immune systems are designed to respond to injury and foreign matter. So, when healthy tissue is mistakenly attacked, the best response that scientific research has come up with is to broadly suppress the immune system. However, this sweeping approach can leave patients open to infection of all kinds and [...]

Other Inflammatory and Autoimmune Diseases2017-04-27T18:12:41+00:00

Immuno-Oncology and Other Therapeutic Areas

2017-04-27T18:12:41+00:00

Immuno-Oncology and Other Therapeutic Areas We do not plan to just beat cancer; we plan to outsmart it. Where past therapies have focused on killing the cancer at any cost, we are learning from the behavior of certain cancers that fool our bodies into thinking that they are benign tissue. By uncovering this behavior, not only [...]

Immuno-Oncology and Other Therapeutic Areas2017-04-27T18:12:41+00:00

Chronic Kidney Disease

2018-06-06T19:20:11+00:00

Chronic Kidney Disease Diabetic nephropathy (DN) is a way of life for about 40 percent of all people who have Type 2 diabetes. Right now, many patients with DN, a form of chronic kidney disease, are prescribed medications, mostly just common blood pressure medications, that are intended to slow its progress. But at ChemoCentryx we [...]

Chronic Kidney Disease2018-06-06T19:20:11+00:00

Job Postings

2018-10-25T04:22:35+00:00

Join Our Team. We seek highly motivated professionals to join our team. We invite you to schedule a visit through Human Resources to learn more about our company and see our current open job postings below. We participate in E-Verify, the US Government sponsored right-to-work verification process. Administration Responsibilities: For [...]

Job Postings2018-10-25T04:22:35+00:00

Other Inflammatory and Autoimmune Diseases

2017-04-27T18:12:42+00:00

Other Inflammatory and Autoimmune Diseases IBD/Crohn’s Disease and Ulcerative Colitis Inflammatory bowel disease (IBD) refers to two diseases - Crohn's disease and ulcerative colitis - both characterized by inflammation of the gastrointestinal tract. Crohn’s disease can cause inflammation in any part of the digestive tract but often affects the tail end of the small intestine. [...]

Other Inflammatory and Autoimmune Diseases2017-04-27T18:12:42+00:00

Board of Directors

2017-08-02T16:02:00+00:00

Thomas J. Schall, Ph.D. President, Chief Executive Officer and Chairman of the Board Thomas A. Edwards Retired Partner, Latham & Watkins, LLP Joseph M. Feczko, M.D. Former Senior Vice President and Chief Medical Officer, Pfizer Inc. Roger C. Lucas, Ph.D. Vice Chairman, Bio-Techne Corporation Geoffrey M. Parker Former Executive Vice President and Chief Financial Officer, Anacor, Inc. James L. Tyree Former Executive Vice President, Abbott Laboratories

Board of Directors2017-08-02T16:02:00+00:00

Overview

2017-04-27T18:12:42+00:00

Overview For years, some of the best medicines were also the most painful - in terms of their side effects and risks. At ChemoCentryx, we believe that great science can lead to better medicine. Our focus on the chemoattractant system is designed to allow us to do better by our patients by providing more [...]

Overview2017-04-27T18:12:42+00:00

Management Team

2018-01-08T16:05:17+00:00

Thomas J. Schall, Ph.D. President, Chief Executive Officer and Chairman of the Board Petrus (Pirow) Bekker, M.D., Ph.D. Chief Medical Officer Markus J. Cappel, Ph.D. Chief Business Officer and Treasurer Susan M. Kanaya Senior Vice President, Finance, Chief Financial Officer and Secretary Israel F. Charo, M.D., Ph.D. Senior Vice President of Research

Management Team2018-01-08T16:05:17+00:00